Mega Lifesciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mega Lifesciences - overview
Established
1982
Location
Bangkok, -, Thailand
Primary Industry
Healthcare
About
Mega Lifesciences, based in Bangkok, Thailand, focuses on health and wellness products, providing a wide array of pharmaceuticals and dietary supplements aimed at improving community health. Founded in 1982 in Bangkok, Thailand, Mega Lifesciences specializes in health products and has established a footprint in various markets. The company has engaged in two significant deals, including a recent acquisition by Lombard of Mega LifeSciences Pty. Ltd.
Financial terms of the deal were not disclosed. Mega We Care specializes in a diverse range of health and wellness products, focusing on pharmaceuticals and dietary supplements. Notable offerings include high-strength B complex vitamins, herbal remedies for coughs and colds, liver protection supplements, and probiotics to support gut health. The company caters to healthcare practitioners, pharmacies, and direct consumers across Myanmar, Vietnam, Cambodia, and the Asia-Pacific region, emphasizing rigorous product quality and efficacy.
For the year 2022, Mega We Care reported a revenue of USD 193. 11 mn and an EBITDA of USD 36. 74 mn. The revenue is generated through a transactional model that involves B2B sales to retailers and wholesalers, as well as direct-to-consumer transactions.
Mega Lifesciences plans to leverage recent funding to enhance its product line, including upcoming launches of innovative health solutions aimed at expanding its reach. The company is targeting market expansion into additional regions, particularly within Southeast Asia, by 2024. The recent acquisition by Lombard reflects a strategic move to strengthen its market position and drive future growth initiatives.
Current Investors
Lombard
Primary Industry
Healthcare
Sub Industries
Alternative Medicine
Website
www.megawecare.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Mega Lifesciences - timeline of key events
Mega Lifesciences - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,241,470,520 | 4,249,979,085 | 4,535,482,028 | 5,257,992,047 | - | - | - |
| % Revenue Growth (YoY) | - | 0.2% | 6.7% | 15.9% | - | - | - |
| EBITDA (USD) | 525,221,464 | 564,916,786 | 231,369,304 | 916,761,263 | - | - | - |
| Operating Income (USD) | 514,407,672 | 556,366,786 | 223,371,304 | 907,527,263 | - | - | - |
| Operating Margin | 12.1% | 13.1% | 4.9% | 17.3% | - | - | - |
| % EBITDA Margin | 12.4% | 13.3% | 5.1% | 17.4% | - | - | - |
| NET Income (USD) | 444,223,817 | 486,113,560 | 570,786,456 | 743,498,969 | - | - | - |
| % Net Margin | 10.5% | 11.4% | 12.6% | 14.1% | - | - | - |
Mega Lifesciences - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Mega Lifesciences | - | ||||||||
| Buyout | Completed | Mega Lifesciences | - |
Displaying 1 - 2 of 2
Mega Lifesciences - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.